Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570850 | 0.80 | PTGS1 (0.65) | PTGS1PTGS2PDPK1KDM4EALDH1A1 | |
| SCHEMBL537395 | 0.80 | PTGS1 (0.65) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL28197895 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL15478687 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL28157524 | 0.79 | PTGS1 (0.68) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL4666357 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL1012734 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2PDPK1KDM4EALDH1A1 | |
| SCHEMBL4978131 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL7330567 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2PDPK1KCNJ6KCNJ5 | |
| SCHEMBL950904 | 0.78 | GRN (0.72) | PTGS1PTGS2KCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212295-B1 | SUBSTITUTED ALPHA-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20050171023-A1 | Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents | CAI SUI X (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1494700-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | Cytovia, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-6495522-B1 | PREVENTING APOPTOTIC CELL DEATH IN WHICH THE LOSS OF CELLS, TISSUES OR ENTIRE ORGANS OCCURS | CYTOVIA, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1212295-A1 | SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016093-A1 | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171023-A1 | Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents | CASP1, CASP3, CASP5 | PTGS1 1263/4885PTGS2 1943/4885PDPK1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.